睿知中国医院研究地图
候选清单

即将招募肺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer

ClinicalTrials.gov 上登记的一项肺癌开放试验,由福建省肿瘤医院牵头,本站收录的另外 3 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 4

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方福建省肿瘤医院Fujian Cancer Hospital福州医院页面
  2. 研究中心福建医科大学附属第一医院First Affiliated Hospital of Fujian Medical University福州医院页面
  3. 研究中心厦门大学附属第一医院First Affiliated Hospital of Xiamen University厦门医院页面
  4. 研究中心福建省立医院Fujian Provincial Hospital福州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06786312,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 9

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(9 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. 1. Patients with extensive stage small cell lung cancer confirmed by histopathology or cytology (excluding complex small cell lung cancer);

    入选标准第 1 条

  3. New York Heart Association (NYHA) heart function Grade > II or left ventricular ejection fraction (LVEF) < 50%;

    排除标准第 10 条

  4. 4. Have not received systematic treatment for extensive small cell lung cancer;

    入选标准第 4 条

    8. BMS must be asymptomatic or treated and stable after discontinuation of steroids and anticonvulsants for at least 1 month prior to study therapy;

    入选标准第 12 条

    3. Presence of symptomatic or active central nervous system (CNS) metastases or cancerous meningitis (patients with asymptomatic or stable brain metastases after treatment are allowed to be included);

    排除标准第 3 条

    12. Subjects who required systemic corticosteroids (> 10 mg/ day effective dose of prednisone) or other immunosuppressive agents within 14 days prior to initial dosing or during the study period. However, in the absence of active autoimmune disease, subjects were allowed to receive topical or inhaled steroids and adrenal hormone replacement therapy at a dose <=10 mg/ day of prednisone effectiveness;

    排除标准第 17 条

  5. 3. The physical status of the Eastern Oncology Consortium (ECOG) was 0 or 1 (see Annex 1 for the ECOGPS scoring criteria);

    入选标准第 3 条

  6. Blood routine test: hemoglobin (Hb) >=90g/L; Absolute neutrophil count (ANC) >=1.5×10\^9/L; Platelet (PLT) >=100×10\^9/L; White blood cell count (WBC) >= 3.0×10\^9/L;

    入选标准第 8 条

    Biochemical examination: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <=2.5×ULN (tumor liver metastasis, <=5×ULN); Serum total bilirubin (TBIL) <=1.5×ULN (Gilbert syndrome subjects, <=3×ULN; In patients with liver metastasis, total bilirubin <=3× ULN); Serum creatinine (Cr) <=1.5×ULN or creatinine clearance >=50ml/min;

    入选标准第 9 条

    Coagulation function: activated partial thromboplastin time (APTT), International standardized ratio (INR), prothrombin time (PT) <=1.5×ULN;

    入选标准第 10 条

  7. 5. Have at least one measurable lesion that meets the RECIST v1.1 standard (see Annex 3);

    入选标准第 5 条

  8. 2. Previous or co-existing malignancies other than cured basal cell carcinoma of the skin, cervical carcinoma in situ, ductal carcinoma in situ of the breast (DCIS), papillary carcinoma of the thyroid gland, and other malignancies that have been adequately treated and cured for ≥5 years prior to the first dose with evidence of no recurrence or metastasis;

    排除标准第 2 条

    Known human immunodeficiency virus (HIV) infection;

    排除标准第 12 条

    Known hepatitis C virus infection (HCV) and HCV RNA positive (>1×103 copies /mL), or other hepatitis, cirrhosis;

    排除标准第 14 条

  9. 9. Women of reproductive age should agree that they must use contraceptives (such as intrauterine devices [IUD], birth control pills or condoms) during the study period and for 6 months after the study ends; Have a negative serum pregnancy test within 28 days prior to study enrollment and must be a non-lactating subject; Men should be subjects who agree to use contraception during the study period and for 6 months after the end of the study period.

    入选标准第 13 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06786312,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. 1. Patients with extensive stage small cell lung cancer confirmed by histopathology or cytology (excluding complex small cell lung cancer);
  2. 2. Age at the time of signing the informed consent: 18-75 years old (including 18 and 75 years old), male or female;
  3. 3. The physical status of the Eastern Oncology Consortium (ECOG) was 0 or 1 (see Annex 1 for the ECOGPS scoring criteria);
  4. 4. Have not received systematic treatment for extensive small cell lung cancer;
  5. 5. Have at least one measurable lesion that meets the RECIST v1.1 standard (see Annex 3);
  6. 6. Expected survival >=3 months;
  7. 7. If the major organs function normally, the following criteria are met:
  8. Blood routine test: hemoglobin (Hb) >=90g/L; Absolute neutrophil count (ANC) >=1.5×10\^9/L; Platelet (PLT) >=100×10\^9/L; White blood cell count (WBC) >= 3.0×10\^9/L;
  9. Biochemical examination: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <=2.5×ULN (tumor liver metastasis, <=5×ULN); Serum total bilirubin (TBIL) <=1.5×ULN (Gilbert syndrome subjects, <=3×ULN; In patients with liver metastasis, total bilirubin <=3× ULN); Serum creatinine (Cr) <=1.5×ULN or creatinine clearance >=50ml/min;
  10. Coagulation function: activated partial thromboplastin time (APTT), International standardized ratio (INR), prothrombin time (PT) <=1.5×ULN;
  11. Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF)>=50%;
  12. 8. BMS must be asymptomatic or treated and stable after discontinuation of steroids and anticonvulsants for at least 1 month prior to study therapy;
  13. 9. Women of reproductive age should agree that they must use contraceptives (such as intrauterine devices [IUD], birth control pills or condoms) during the study period and for 6 months after the study ends; Have a negative serum pregnancy test within 28 days prior to study enrollment and must be a non-lactating subject; Men should be subjects who agree to use contraception during the study period and for 6 months after the end of the study period.
  14. 10. Subjects voluntarily joined the study, signed informed consent, had good compliance, and cooperated with follow-up.

排除标准:Exclusion Criteria:

  1. 1. Known allergy to any of the drugs in the study;
  2. 2. Previous or co-existing malignancies other than cured basal cell carcinoma of the skin, cervical carcinoma in situ, ductal carcinoma in situ of the breast (DCIS), papillary carcinoma of the thyroid gland, and other malignancies that have been adequately treated and cured for ≥5 years prior to the first dose with evidence of no recurrence or metastasis;
  3. 3. Presence of symptomatic or active central nervous system (CNS) metastases or cancerous meningitis (patients with asymptomatic or stable brain metastases after treatment are allowed to be included);
  4. 4. Active or previously suffering from autoimmune disease or immune deficiency;
  5. 5. In the first study, patients with clinically significant bleeding symptoms or bleeding tendency, such as hemoptysis, hematemesis, hematochezia, gastrointestinal bleeding, hemorrhagic gastric ulcer, etc., occurred within 3 months before medication;
  6. 6. Imaging (CT or MRI) shows that the tumor has invaded the large blood vessels or the boundary with the large blood vessels is unclear; Or if the investigator determines that the subject's tumor has a high risk of invading vital blood vessels during treatment and causing fatal bleeding;
  7. 7. Have high blood pressure that is not well controlled by antihypertensive medication (systolic blood pressure >= 150mmHg or diastolic blood pressure >= 100 mmHg);
  8. 8. Cardiovascular and cerebrovascular diseases of significant clinical significance:
  9. Cerebrovascular accident (excluding lacunar infarction, minor cerebral ischemia, or transient ischemic attack), myocardial infarction, unstable angina pectoris, and poorly controlled arrhythmias (including QTc interval >= 450ms for men and 470 ms for women) occurred within 6 months before the first administration of the study drug (QTc interval >= 450ms for women) Fridericia formula);
  10. New York Heart Association (NYHA) heart function Grade > II or left ventricular ejection fraction (LVEF) < 50%;
  11. 9. Active or uncontrolled severe infection;
  12. Known human immunodeficiency virus (HIV) infection;
  13. Known history of clinically significant liver disease, including viral hepatitis [active HBV infection, i.e., HBV DNA positive (>1×104 copies /mL or >2000 IU/ml) must be excluded for a known HBV carrier;
  14. Known hepatitis C virus infection (HCV) and HCV RNA positive (>1×103 copies /mL), or other hepatitis, cirrhosis;
  15. 10. Patients with uncontrolled pleural effusion, pericardial effusion or peritoneal effusion in the third space, as judged by researchers, requiring puncture and drainage; Or received ascites, pleural effusion drainage within 14 days before the first medication;
  16. 11. Patients with interstitial pneumonia or interstitial lung disease, or a history of interstitial pneumonia or interstitial lung disease requiring hormone therapy, or other pulmonary fibrosis, chronic pneumonia, pneumonia due to drug or radiation therapy, a history of congenital pneumonia, or any evidence of active pneumonia on chest CT scan that may interfere with the judgment of immune-related pulmonary toxicity; Patients with severe impairment of lung function confirmed by current pulmonary function examination;
  17. 12. Subjects who required systemic corticosteroids (> 10 mg/ day effective dose of prednisone) or other immunosuppressive agents within 14 days prior to initial dosing or during the study period. However, in the absence of active autoimmune disease, subjects were allowed to receive topical or inhaled steroids and adrenal hormone replacement therapy at a dose <=10 mg/ day of prednisone effectiveness;
  18. 13. The subject has any current disease or condition that affects drug absorption, or the subject is unable to take apatinib orally;
  19. 14. Urine routine indicated urinary protein >=2+, and 24-hour urinary protein quantity >1.0g;
  20. 15. The investigator considers that the subject is not suitable to participate in the clinical study due to any clinical or laboratory abnormalities or other reasons.

引自 ClinicalTrials.gov, NCT06786312, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06786312,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06786312